`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`__________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`__________________
`
`BECTON, DICKINSON AND COMPANY,
`
`Petitioner,
`
`v.
`
`B. BRAUN MELSUNGEN AG,
`
`Patent Owner.
`
`__________________
`
`Case IPR2017-01588
`Patent No. 8,460,247
`
`__________________
`
`DECLARATION OF WILLIAM G. MCELWAIN IN SUPPORT OF
`MOTION FOR ADMISSION PRO HAC VICE
`
`BD 1041
`BD v. B. BRAUN
`IPR2017-01588
`
`
`
`
`
`I, William G. McElwain, declare as follows:
`
`Case No. IPR2017-01588
`McElwain Declaration
`
`
`
`1.
`
`I was admitted to the Massachusetts Bar in December of 1982, the
`
`District of Columbia Bar in March of 1986, and the Virginia Bar in
`
`October of 1989. I have been practicing law for 36 years. For more
`
`than 25 years, my practice has focused primarily on patent litigation.
`
`2. Over the course of my career, I have been counsel in dozens of patent
`
`litigations.
`
`3.
`
`I am a member in good standing in the Bars of Massachusetts, the
`
`District of Columbia, and Virginia and am admitted to practice before
`
`the U.S. District Courts for the District of Columbia, District of
`
`Maryland, and District of Massachusetts. I am also admitted to
`
`practice before the U.S. Court of Appeals for the Federal Circuit and
`
`the United States Supreme Court.
`
`4. My Massachusetts Bar membership number is 332510. My District of
`
`Columbia Bar membership number is 397553. My Virginia Bar
`
`membership number is 30732.
`
`5.
`
`I have never been suspended or disbarred from practice before any
`
`court or administrative body.
`
`1
`
`
`
`
`
`
`I have never had a court or administrative body deny my application
`
`Case No. IPR2017-01588
`McElwain Declaration
`
`
`
`6.
`
`for admission to practice.
`
`7.
`
`I have read and will comply with the Patent Office Trial Practice
`
`Guide and the Board’s Rules for Practice for Trials, as set forth in 37
`
`C.F.R. Part 42.
`
`8.
`
`I agree to be subject to the United States Patent and Trademark Office
`
`Rules of Professional Conduct set forth in 37 C.F.R. §§ 11.101 et seq.
`
`and disciplinary jurisdiction under 37 C.F.R. § 11.19(a).
`
`9.
`
`I have applied to appear pro hac vice in the following proceedings
`
`before the United States Patent and Trademark Office in the last three
`
`years: Coherus Biosciences Inc. v. AbbVie Biotechnology Ltd., Case
`
`IPR2016-00172; Coherus Biosciences Inc. v. AbbVie Biotechnology
`
`Ltd., Case IPR2016-00188; Coherus Biosciences Inc. v. AbbVie
`
`Biotechnology Ltd., Case IPR2016-00189; Boerhringer Ingelheim
`
`Int’l. GmbH v. AbbVie Biotechnology Ltd., Case IPR2016-00408; and
`
`Boerhringer Ingelheim Int’l. GmbH v. AbbVie Biotechnology Ltd.,
`
`Case IPR2016-00409.
`
`10. I am intimately familiar with the subject matter of U.S. Patent No.
`
`
`
`
`2
`
`
`
`8,460,247, as I am counsel in the related district court litigation and
`
`Case No. IPR2017-01588
`McElwain Declaration
`
`
`
`appeal, B. Braun Melsungen AG v. Becton, Dickinson and Co., Civ.
`
`No. 1:16-cv-00411-RGA (D. Del.), and its appeal, B Braun Melsungen
`
`AG v. Becton, Dickinson and Company, Appeal No. 2018-1497 (Fed.
`
`Cir.).
`
`11. In addition to this matter, I have represented Becton, Dickinson and
`
`Company or its affiliates in multiple patent and patent-related cases,
`
`including: B. Braun Melsungen AG v. Becton, Dickinson and Co., Civ.
`
`No. 1:16-cv-00411-RGA (D. Del.), and its appeal, B Braun Melsungen
`
`AG v. Becton, Dickinson and Company, Appeal No. 2018-1497 (Fed.
`
`Cir.); Safety Syringes Inc v. Becton Dickinson, Civ. No. 3:01-cv-2031-
`
`J NLS (S.D. Cal.); MBO Laboratories. v. Becton, Dickinson & Co.,
`
`Appeal Nos. 2011-1446 and 2008-1446 (Fed. Cir.); Becton Dickinson
`
`and Co. v. Tyco Healthcare Group LP, Civ. No. 1:02-cv-1694 (D.
`
`Del.), and its appeal Becton, Dickinson & Co. v. Tyco Healthcare
`
`Group, Appeal No. 2009-1053 (Fed. Cir.); Retractable Technologies,
`
`Inc. v. Becton Dickinson and Co., Civ. No. 2:07-cv-00250 (E.D. Tex.),
`
`and its appeals, Retractable Techs., Inc. v. Becton, Dickinson & Co.,
`
`
`
`
`3
`
`
`
`Appeal Nos. 2010-1402 and 2013-1567 (Fed. Cir.); Becton Dickinson
`
`Case No. IPR2017-01588
`McElwain Declaration
`
`
`
`and Co. v. Retractable Technologies, Inc., Civ. No. 5:07-cv-00137-
`
`ALM-CMC (E.D. Tex.); Vaillancourt v. Becton Dickinson & Co.,
`
`Appeal No. 2013-1408 (Fed. Cir.); Enzo Life Sciences Inc., v. Becton
`
`Dickinson and Co., Civ. No. 1:12-cv-00275 (D. Del.); Becton
`
`Dickinson Diagnostics Inc.; and Geneohm Sciences, Inc., Civ. No.
`
`1:12-cv-00275-LPS (D. Del.); One Stockduq Holdings, LLC v. Becton,
`
`Dickinson and Company, Civ No. 2:12-cv-03037 (W.D. Tenn.), and
`
`its appeal, One Stockduq Holdings, LLC v. Becton, Dickinson and
`
`Company, Appeal No. 15-1255 (Fed. Cir.); Antares Pharma, Inc., v.
`
`Medac Pharma, Inc. and Medac GMBH, Civ. No. 1:14-cv-00270-SLR
`
`(D. Del.).
`
`12. I am familiar with IV catheter technology as a result of my
`
`participation as counsel in prior cases related to that technology,
`
`including One Stockduq Holdings, LLC v. Becton, Dickinson and
`
`Company, Civ No. 2:12-cv-03037 (W.D. Tenn.), and its appeals, One
`
`Stockduq Holdings, LLC v. Becton, Dickinson and Company, Appeal
`
`No. 15-1255 (Fed. Cir.); and Vaillancourt v. Becton Dickinson & Co.,
`
`
`
`
`4
`
`
`
`Appeal No. 2013-1408 (Fed. Cir.). I am also familiar with related
`
`Case No. IPR2017-01588
`McElwain Declaration
`
`
`
`medical device technology, such as syringes, as a result of my
`
`participation as counsel in prior cases related to that technology,
`
`including Retractable Technologies, Inc., et al. v. Becton Dickinson
`
`and Co., Civ. No. 2:07-cv-250 (E.D. Tex.), and its appeals,
`
`Retractable Tech., Inc. v. Becton, Dickinson & Co., Appeal Nos.
`
`2010-1402 and 2013-1567 (Fed. Cir.). In addition, I have represented
`
`a number of life sciences and medical devices companies—Becton,
`
`Dickinson and Company, AbbVie Biotechnology Ltd., F. Hoffman-
`
`LaRoche Ltd., GlaxoSmithKline LLC and others—in many patent
`
`litigation matters before federal district courts, appellate courts, and
`
`arbitration tribunals. The technology involved in these disputes
`
`includes, e.g., IV catheters, syringes, pharmaceuticals compounds, and
`
`nucleic acid detection and hybridization.
`
`13. I hereby declare that all statements made herein of my own knowledge
`
`are true and that all statements made on information and belief are
`
`believed to be true; and further that these statements are made with the
`
`knowledge that willful false statements and the like are punishable by
`
`
`
`
`5
`
`
`
`fine, imprisonment, or both under Section 1001 of Title 18 of the
`
`Case No. IPR2017-01588
`McElwain Declaration
`
`
`
`United States Code.
`
`
`Dated: May 2, 2018
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted
`
`/William G. McElwain/
`William G. McElwain
`WILMER CUTLER PICKERING HALE AND
`DORR LLP
`1875 Pennsylvania Avenue, NW
`Washington, DC 20006
`(202) 663-6388
`
`6
`
`